to_name,to_email,company,subject,body
Mitsuaki Sekiguchi,mitsuaki.sekiguchi@shionogi.co.jp,"Shionogi & Co., Ltd",原薬評価の実務負荷を軽減するご提案,"Mitsuaki Sekiguchi 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

API R&Dの現場では、原薬（API）候補の評価対象が増加し、文献精査や資料整理に多くの時間を割かれているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご都合の良いお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kinichi Imura,kinichi.imura@shionogi.co.jp,"Shionogi & Co., Ltd",新規事業推進×AI導入のご提案,"Kinichi Imura 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

井村様がイノベーション・インキュベーショングループを統括され、新規事業創出を推進されていることを拝見いたしました。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
監査証跡とガバナンス対応も標準装備しており、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京にてお目にかかれればと存じます。ご都合の良いお時間帯をお知らせいただけますでしょうか。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Tomoko Niimi,tomoko.niimi@shionogi.co.jp,"Shionogi & Co., Ltd",BD案件評価の実務負荷軽減ツール,"Tomoko Niimi 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

BD案件が加速されている状況かと存じます。案件増加に伴い、初期評価やドキュメント整理の負荷も高まっているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお会いできましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Mark Hill,mark.hill@shionogi.eu,"Shionogi & Co., Ltd",In-Licensing Screening Tool for Shionogi's Scientific Ops,"Dear Mr. Hill,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing teams.

With Shionogi's growing global BD activity, including the ViiV stake increase, your Scientific Operations team is likely handling a higher volume of asset evaluations.

Much of that early-stage screening work -- gathering documents, extracting data, assembling evaluation packs -- still involves significant manual effort. Our In-Licensing Workflow AI is an on-premise tool designed to help reduce that workload. Specifically, it:

- Automates document extraction and structured data organization
- Generates standardized evaluation packs with audit trail
- Runs entirely on-premise for data security

I will be in Tokyo on February 16-17 and would welcome a 20-30 minute meeting. A Zoom call also works if in-person timing does not fit.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Could you let me know if either day works?

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Jared Grobels,jgrobels@shionogi.com,Shionogi,Reducing Screening Workload for Shionogi BD,"Dear Mr. Grobels,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

With Shionogi actively pursuing in-licensing and strategic M&A, your BD team is likely managing a heavy deal flow. The early screening steps -- pulling together documents, extracting structured data, and building decision packs -- involve significant manual work.

Our In-Licensing Workflow AI is designed to help reduce that workload. It runs on-premise and handles:

- Structured data extraction from source documents
- Standardized risk and gap analysis
- Decision Pack generation with full audit trail

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom is also fine if scheduling is tight.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Alistair Phayme,alistair.phayme@shionogi.com,Shionogi,Workflow Tool for BD Project Evaluation at Shionogi,"Dear Mr. Phayme,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

Managing BD project workflows at Shionogi, with the ViiV stake increase and ongoing in-licensing activity, means coordinating structured evaluations across multiple teams. A lot of the initial screening and document assembly work still involves significant manual effort.

Our In-Licensing Workflow AI is an on-premise tool designed to help reduce time spent on those steps:

- Organizes and extracts data from source documents
- Assembles standardized Decision Packs
- Maintains full audit trail and governance compliance

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom is also available if needed.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Takeshi Aoki,takeshi.aoki@shionogi.co.jp,"Shionogi & Co., Ltd",CNS領域の案件評価を効率化,"Takeshi Aoki 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

CNS領域を重点的に展開される中、外部候補の科学的評価にも多くのリソースを割かれているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
文書からの構造化データ抽出やリスクギャップ分析にも対応し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお会いできましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yasuyuki Ariyasu,yasuyuki.ariyasu@shionogi.co.jp,"Shionogi & Co., Ltd",臨床開発の案件評価を効率化するAI,"Yasuyuki Ariyasu 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

臨床開発部門では、評価対象案件が増加し、候補の精査に多くの時間を費やされているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でご説明の機会をいただけましたら幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Wenjing Zhao,wenjing.zhao@shionogi.com,Shionogi,Tool for BD Assessment Screening at Shionogi,"Dear Ms. Zhao,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

Leading BD Assessment and New Product Planning at Shionogi, you are at the center of evaluating in-licensing opportunities. With deals like the RADICAVA acquisition agreement underway, the volume of candidates to screen is likely growing.

The early-stage assessment work -- collecting data, structuring documents, and building evaluation packs -- involves significant manual effort. Our In-Licensing Workflow AI is designed to help reduce that:

- Extracts and structures data from source documents
- Generates standardized evaluation and Decision Packs
- Runs on-premise with full audit trail

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom is also available.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masaaki Sasaoka,masaaki.sasaoka@shionogi.co.jp,"Shionogi & Co., Ltd",BD技術評価の効率化ご提案,"Masaaki Sasaoka 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

BD部門テクノロジーグループにて、案件の技術評価を担当されている笹岡様にご連絡いたしました。
インライセンス案件の増加に伴い、技術デューデリジェンスの負荷も高まっているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
文書の構造化データ抽出やリスクギャップ分析にも対応し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお会いできましたら幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hiroki Ozasa,hiroki.ozasa@shionogi.co.jp,"Shionogi & Co., Ltd",インライセンス評価の負荷軽減ツール,"Hiroki Ozasa 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

インライセンス案件の評価対象が増加されているのではと拝察いたします。
日々の案件スクリーニング業務も相当な量になっているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
監査証跡機能も標準搭載しており、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望の時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Keisuke Kusumoto,keisuke.kusumoto@shionogi.co.jp,"Shionogi & Co., Ltd",CVC投資評価の効率化ご提案,"Keisuke Kusumoto 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

楠本様がCVCおよび経営企画部門を統括され、戦略的投資を推進されていることを拝見いたしました。
投資案件の評価・分析プロセスにおいて、候補の精査に多くの工数がかかっているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
リスク分析機能も備え、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masahide Fujita,masahide.fujita@shionogi.co.jp,"Shionogi & Co., Ltd",ライセンシング業務の効率化ご提案,"Masahide Fujita 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

藤田様がライセンシング・トランザクションユニットを統括されていると存じております。
トランザクション案件が増加する中、評価プロセスの効率化が一層重要になっているかと存じます。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
構造化データ抽出と標準化評価フレームワークを備え、監査証跡も完備しております。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Toshiyuki Asaki,toshiyuki.asaki@shionogi.co.jp,"Shionogi & Co., Ltd",創薬研究の外部候補評価を効率化,"Toshiyuki Asaki 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

浅木様が執行役員SVPとして創薬研究本部を統括されている中、CNS領域や感染症領域で外部候補の探索・評価を積極的に進められていると拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
構造化データ抽出やリスクギャップ分析にも対応し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masatomo Rokushima,masatomo.rokushima@shionogi.co.jp,"Shionogi & Co., Ltd",ワクチンR&Dの評価プロセス効率化,"Masatomo Rokushima 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

感染症領域を中核に据え、ワクチンR&Dを重点的に推進される中、六島様のラボでも外部技術や評価候補の案件が増加されているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお会いできませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Teruhiko Taishi,teruhiko.taishi@shionogi.co.jp,"Shionogi & Co., Ltd",製薬開発PMの評価プロセス効率化,"Teruhiko Taishi 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大石様が製薬開発プロジェクトマネジメントを統括される中、パイプライン拡大に伴い評価・意思決定プロセスの複雑性も増しているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
部門横断の評価チームの効率化に貢献し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
John Keller,jkeller@shionogi.com,"Shionogi & Co., Ltd",AI Screening Tool for Shionogi R&D Pipeline,"Dear Mr. Keller,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

As SVP overseeing Shionogi's R&D Supervisory Unit, you have visibility across every asset entering the pipeline. With the expanding infectious disease and CNS portfolios, the volume of assets to evaluate keeps growing.

The initial screening work -- extracting data, reviewing documents, assembling evaluation packs -- involves significant manual effort at each stage. Our In-Licensing Workflow AI is designed to help reduce that workload:

- Automates data extraction and document structuring
- Generates standardized Decision Packs
- Runs on-premise with full governance compliance and audit trail

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom is also available if scheduling is tight.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Keiichi Ono,keiichi.ono@shionogi.co.jp,"Shionogi & Co., Ltd",ワクチン処方R&Dの評価効率化AI,"Keiichi Ono 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

感染症領域を中核戦略に据え、ワクチン開発を推進される中、小野様の処方R&D部門でも外部技術や候補化合物の評価業務が増えているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
文書からの構造化データ抽出やリスクギャップ分析にも対応し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Soichi Shiono,sshiono@shionogi.com,"Shionogi & Co., Ltd",Screening Tool for Alliance & In-Licensing Evaluation,"Dear Mr. Shiono,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

Heading Alliance Management and Investment at Shionogi, you are evaluating both partnership opportunities and new in-licensing candidates. With the ViiV relationship (now at 21.7% stake) alongside ongoing deal sourcing, the evaluation workload is considerable.

Much of the initial screening -- gathering documents, extracting structured data, building evaluation packs -- still involves significant manual work. Our In-Licensing Workflow AI is designed to help reduce that:

- Structures and extracts data from source documents
- Automates risk/gap analysis and Decision Pack generation
- Runs on-premise with complete audit trail

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom also works if needed.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masashi Deguchi,masashi.deguchi@shionogi.co.jp,"Shionogi & Co., Ltd",DX推進×インライセンスAI導入,"Masashi Deguchi 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

出口様が執行役員SVPとしてDX推進本部を統括され、全社のデジタル化を牽引されていることを拝見いたしました。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
監査証跡・ガバナンス対応も完備しております。

DX推進施策の一環として、BD部門への展開をご検討いただけませんでしょうか。初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお目にかかれれば幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ken-Ichi Kusakabe,ken-ichi.kusakabe@shionogi.co.jp,"Shionogi & Co., Ltd",CNS創薬の外部候補評価を効率化,"Ken-Ichi Kusakabe 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

日下部様がニューロサイエンス・ケミストリー部門を統括される中、CNSプログラムを積極的に推進されていると拝察いたします。
外部候補の科学的評価にも多くのリソースが必要ではないでしょうか。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
文書の構造化データ抽出やリスクギャップ分析にも対応し、初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお会いできませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Mitsuru Yamamoto,mitsuru.yamamoto@shionogi.co.jp,"Shionogi & Co., Ltd",BD案件スクリーニングの効率化AI,"Mitsuru Yamamoto 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

BD案件が活発に進行される中、現場でのスクリーニングやドキュメント整理にも大きな負荷がかかっているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補探索から評価分析、検討資料（Decision Pack）の自動作成までをオンプレミスで自動化するソリューションです。
初期スクリーニングの実務負荷の軽減に寄与いたします。

2月16～17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yuji Kando,yuji.a.kando@jt.com,"Shionogi & Co., Ltd",AI Tool for In-Licensing Screening at Shionogi,"Dear Mr. Kando,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

As Director of In-Licensing at Shionogi's BD division, you are directly responsible for sourcing and evaluating external assets. With Shionogi's recent activity around the RADICAVA consideration, the volume of candidates to screen is likely growing.

The early-stage work -- gathering documents, extracting data, building standardized evaluation packs -- involves significant manual effort. Our In-Licensing Workflow AI is designed to help reduce that:

- Automates structured data extraction from source documents
- Generates standardized evaluations and Decision Packs
- Runs on-premise with full audit trail compliance

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom is also available.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Junichi Onuma,jonuma@aculys.com,Aculys Pharma,Screening Tool for Aculys's In-Licensing Pipeline,"Dear Onuma-san,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

With pitolisant's NDA progress in Japan and Aculys building its pipeline under Viatris, your clinical development team is likely evaluating a growing number of in-licensing candidates. Screening overseas-approved assets for Japan-specific regulatory fit involves significant manual work.

Our In-Licensing Workflow AI is an on-premise tool designed to help reduce that screening workload:

- Extracts and structures clinical and regulatory data from source documents
- Generates standardized evaluation packs with audit trail
- Runs entirely on-premise for data security

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom also works if in-person timing does not fit.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masaru Matsuoka,mmatsuoka@aculys.com,Aculys Pharma,Streamlining Asset Evaluation at Aculys Medical,"Dear Matsuoka-san,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

Aculys's focus on bringing overseas-approved CNS therapies to Japan means your medical division is central to every asset evaluation. Assembling clinical and regulatory data across multiple sources for each candidate involves significant manual work.

Our In-Licensing Workflow AI is an on-premise tool designed to help reduce that effort:

- Extracts and structures clinical data from source documents
- Produces standardized evaluation frameworks and risk/gap analysis
- Maintains full audit trail compliance

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work to walk through how this could fit Aculys's workflow? Zoom also works if scheduling is tight.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hidemasa Tanigaki,htanigaki@aculys.com,Aculys Pharma,In-Licensing Workflow Tool for Aculys,"Dear Tanigaki-san,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

Aculys's core strategy -- licensing overseas-approved CNS drugs into Japan, with pitolisant's NDA progress as a recent milestone -- means in-licensing evaluation is a constant and growing workload. Much of the early screening still involves significant manual effort: gathering documents, structuring data, and assembling evaluation packs.

Our In-Licensing Workflow AI is an on-premise tool designed to help reduce that workload:

- Automates document organization and structured data extraction
- Generates standardized Decision Packs with audit trail
- Runs entirely on-premise for governance compliance

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work on either day? Zoom also works if timing does not align.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kazunori Shibata,kshibata@aculys.com,Aculys Pharma,On-Premise Evaluation Tool with Audit Trail for Aculys,"Dear Shibata-san,

My name is Imsoo Ryoo, Co-Founder at RISORIUS. We build AI tools for pharma in-licensing workflows.

As Aculys scales its in-licensing pipeline under Viatris, governance and compliance across a growing volume of asset evaluations becomes increasingly important. Tracking decision rationale, document lineage, and cross-functional approvals through manual processes can become a bottleneck.

Our In-Licensing Workflow AI is an on-premise tool with built-in audit trail and governance compliance. It is designed to help reduce screening workload while keeping every decision fully traceable:

- Automates document organization and data extraction
- Generates Decision Packs with complete audit trail
- Runs on-premise -- no data leaves your environment

I will be in Tokyo on February 16-17. Would a 20-30 minute meeting work to discuss how this aligns with Aculys's operational needs? Zoom also works if in-person is not feasible.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Takayuki Hara,hara.takayuki@nobelpharma.co.jp,Nobelpharma Co. LTD,導入検討における実務負荷の軽減について,"Takayuki Hara 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

ノーベルファーマ様は希少疾病・アンメットメディカルニーズに注力され、着実にパイプラインを拡大されていると拝察いたします。

海外候補の日本向け導入評価において、資料整理やデータ抽出、リスク分析に工数がかかる場面もあるのではないかと存じます。

弊社のイン・ライセンシングワークフローAIは、候補探索から評価分析、Decision Packの自動作成まで一連の業務を自動化するオンプレミス型のツールです。
初期スクリーニングの実務負荷の軽減に寄与できるかと考えております。監査証跡・ガバナンス対応も備えております。

2月16日・17日に東京におりますので、30分ほどお時間を頂戴できますと幸いです。対面が難しい場合はZoomでも対応可能です。
ご都合の良いお時間帯をお知らせいただけますでしょうか。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Katsu Endo,endo.katsu@nobelpharma.co.jp,Nobelpharma Co. LTD,導入評価の標準化による意思決定支援について,"Katsu Endo 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

ノーベルファーマ様は医薬品に加え医療機器分野でも導入を推進されており、評価対象の多様化に伴い、部門横断での意思決定プロセスがますます重要になられているかと存じます。

導入候補の評価資料を手作業で整理・分析されている場合、標準的な評価の枠組みがあることで、意思決定の効率化に寄与できる面もあるかと存じます。

弊社のイン・ライセンシングワークフローAIは、データ抽出・評価フレームワーク・リスク分析を自動化し、スクリーニングの実務負荷を軽減するオンプレミス型のツールです。
監査証跡も備えております。

2月16〜17日に東京へ参りますので、対面でご説明の機会を頂けますと幸いです。Zoomでも可能ですので、ご都合の良い時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kusayanagi,kusayanagi@nobelpharma.co.jp,Nobelpharma Co. LTD,R&D評価業務の効率化について,"Kusayanagi 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

ノーベルファーマ様のR&D部門では、希少疾病領域の導入候補について、文献やデータの精査に多くのお時間を費やされているのではないかと存じます。

弊社のイン・ライセンシングワークフローAIは、文書からのデータ抽出や評価、リスク・ギャップ分析まで一連の業務を自動化するオンプレミス型のツールです。
初期スクリーニングの実務負荷の軽減にお役立ていただけるかと考えております。

2月16〜17日に東京におりますので、直接ご説明の機会を頂ければ幸いです。Zoomも対応可能です。
ご都合をお知らせいただけますでしょうか。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Tokuhisa Yamato,tokuhisa_yamato@pharm.kissei.co.jp,Kissei Pharmaceutical Co Ltd,導入案件スクリーニングの効率化について,"Tokuhisa Yamato 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

キッセイ薬品様はViridian社とのTED案件（7,000万ドル）やBoston OIオフィスの設立など、イン・ライセンシングを積極的に推進されていると拝察いたします。

海外案件の増加に伴い、臨床プロジェクト管理の観点から、候補資産の評価・分析業務の効率化が重要課題ではないでしょうか。

弊社のイン・ライセンシングワークフローAIは、候補探索からDecision Packの自動作成まで一連のプロセスを自動化し、初期スクリーニングの実務負荷の軽減に寄与いたします。
オンプレミス対応・監査証跡を備えたソリューションです。

2月16〜17日に東京本社付近へ参ります。30分ほどお時間を頂戴できますでしょうか。対面が難しい場合はZoomでも可能です。
ご希望の時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Tomoyuki Terayama,tomoyuki_terayama@pharm.kissei.co.jp,Kissei Pharmaceutical Co Ltd,BD業務における評価プロセスの効率化について,"Tomoyuki Terayama 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

キッセイ薬品様はViridian社TED案件やBoston OIオフィスなど、イン・ライセンシングを事業の柱として強化されているかと存じます。
BD部門のご担当として、候補探索から社内評価資料の作成まで、幅広い業務を担われているのではないでしょうか。

弊社のイン・ライセンシングワークフローAIは、候補探索から評価分析、Decision Pack作成まで一連の業務を自動化するオンプレミス型のツールです。
スクリーニングの実務負荷の軽減に寄与できるかと考えております。

2月16〜17日に東京へ参ります。お時間を頂ければ直接ご説明させていただきます。Zoomも対応可能です。
ご都合の良いお時間帯をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hidetoshi Suzuki,hidetoshi_suzuki@pharm.kissei.co.jp,Kissei Pharmaceutical Co Ltd,導入評価プロセスの効率化について,"Hidetoshi Suzuki 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

キッセイ薬品様はViridian社との大型提携やBoston拠点の設立など、グローバルなイン・ライセンシング体制を構築されていると拝察いたします。

BD部門では、海外の導入候補に関する文献精査やデータ整理、評価レポート作成に多くのお時間を費やされている面もあるのではないかと存じます。

弊社のワークフローAIは、データ抽出からDecision Pack作成まで一連の業務を自動化し、初期スクリーニングの実務負荷の軽減に寄与いたします。
オンプレミス対応で監査証跡も備えております。

2月16〜17日に東京へ参りますので、直接お話しする機会を頂ければ幸いです。Zoomも対応可能です。
ご都合をお知らせいただけますと幸いです。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Jo Longland,jo.longland@nxera.life,Nxera Pharma,Reducing Manual Screening Across 7 Pipeline Programs,"Dear Longland-san,

With Nxera managing 7 active pipeline programs, your team is likely reviewing a steady flow of licensing candidates alongside ongoing R&D work.

For many BD teams in this situation, the time spent organizing documents, extracting data, and preparing evaluation summaries for each candidate adds up quickly.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps in the process:

- Structured data extraction and candidate evaluation from incoming documents
- Risk/gap analysis and Decision Pack generation for internal review
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17 and would welcome a brief meeting. Zoom also works if that is more convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Sital Kotecha,sital.kotecha@nxera.life,Nxera Pharma,On-Premise AI for Pharma Licensing Workflows,"Dear Kotecha-san,

With Nxera operating across 7 active pipeline programs, any new internal tool needs to meet strict requirements around data security, integration, and governance.

Our In-Licensing Workflow AI was built with those constraints in mind. It runs fully on-premise — no data leaves your environment — and automates key steps in the asset evaluation process:

- Document ingestion and structured data extraction
- Evaluation analysis and Decision Pack generation
- Built-in audit trail and governance compliance, no cloud dependencies

It is designed to reduce the manual screening workload that BD and R&D teams typically carry.

I will be in Tokyo February 16–17. Could we find 30 minutes to discuss how this fits Nxera’s infrastructure? Zoom also works if scheduling in person is difficult.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Lise Peronnaud,lise.peronnaud@nxera.life,Nxera Pharma,Automating Licensing Evaluation Across Nxera’s Portfolio,"Dear Peronnaud-san,

With Nxera’s portfolio spanning discovery through development, your team is likely handling a continuous flow of licensing candidates that each require structured assessment.

Preparing those assessments — gathering documents, extracting relevant data, building evaluation summaries — tends to be one of the more time-consuming parts of the process.

Our In-Licensing Workflow AI is designed to reduce that effort by automating key steps:

- Structured data extraction and standardized evaluation from source documents
- Risk/gap analysis and auto-generated Decision Packs
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17 and would be glad to meet. Zoom is also an option if that is easier.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Marcus Messenger,marcus@nxera.life,Nxera Pharma,Reducing Screening Workload for Nxera BD,"Dear Messenger-san,

With Nxera managing an active license-out and royalty model across 7 pipeline programs, your BD team is likely evaluating multiple opportunities in parallel at any given time.

The operational side of that — organizing documents, extracting data, building evaluation packs for each candidate — can become a bottleneck as deal volume grows.

Our In-Licensing Workflow AI is designed to reduce that screening workload by automating key steps:

- Document organization, structured evaluation, and Decision Pack generation
- On-premise deployment with audit trail and governance compliance

I will be in Tokyo February 16–17. Could we find 30 minutes to meet? Zoom works just as well if in-person scheduling is difficult.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kenshi Hironaka,kenshi.hironaka@nxera.life,Nxera Pharma,On-Premise Licensing AI — Technical Overview for Nxera,"Dear Hironaka-san,

Supporting business applications across Nxera’s operations — with both commercial products and 7 pipeline programs in development — means every new tool needs to integrate cleanly and meet your security standards.

Our In-Licensing Workflow AI was built for that kind of environment:

- Fully on-premise, no external data transfer required
- Automates candidate screening, document extraction, and Decision Pack generation
- Includes audit trail and governance compliance by default

It is designed to reduce the manual screening workload in asset evaluation workflows.

I would welcome the chance to walk through the technical architecture. I will be in Tokyo February 16–17 — could we meet briefly? Zoom works too.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yen Chen,y-chen@peptidream.com,PeptiDream,Streamlining Alliance Evaluation at PeptiDream,"Dear Chen-san,

With PeptiDream’s broad alliance portfolio, your team is managing ongoing partnership evaluation across multiple stakeholders — each opportunity requiring its own data assembly and decision documentation.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps in the evaluation process:

- Structured data extraction and standardized candidate evaluation
- Risk/gap analysis and auto-generated Decision Packs
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17. Could we find 30 minutes to meet? Zoom also works if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Makoto Jitsuoka,m-jitsuoka@peptidream.com,PeptiDream,Reducing R&D Screening Time at PeptiDream,"Dear Jitsuoka-san,

PeptiDream’s platform partnerships generate a continuous flow of R&D evaluation needs, with each engagement requiring thorough scientific and strategic assessment.

For R&D teams, the time spent organizing documents, extracting structured data, and building evaluation reports for each opportunity can become a real constraint.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Document extraction and structured data organization
- Evaluation analysis and Decision Pack generation
- On-premise deployment with built-in audit trail

I will be in Tokyo February 16–17. Would a 30-minute meeting work? Zoom is also an option if scheduling in person is difficult.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Christian Cunningham,c-cunningham@peptidream.com,PeptiDream,AI for Partnership Screening at PeptiDream,"Dear Cunningham-san,

As CSO at PeptiDream, you are constantly assessing where the company’s platform technology fits with potential partners — and each evaluation requires careful scientific and strategic analysis.

As partnership volume grows, the manual work of screening candidates, extracting data, and preparing evaluation materials can take up a disproportionate share of your team’s time.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Structured data extraction and standardized evaluation frameworks
- Risk/gap analysis and Decision Pack generation
- On-premise deployment with full audit trail and governance compliance

I will be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yasushi Yoshimi,yasushi.yoshimi@meiji.com,Meiji Seika Kaisha Ltd,AI for Licensing Evaluation at Meiji Seika,"Dear Yoshimi-san,

With Meiji Seika expanding its open innovation efforts — including the MBC BioLabs partnership announced in late 2025 — the volume of external asset candidates coming through for evaluation is likely growing.

For teams supporting that strategy, each candidate still needs thorough assessment: document review, data extraction, and structured analysis before decisions move forward.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Document organization and structured data extraction
- Evaluation analysis and Decision Pack generation
- On-premise deployment with built-in audit trail

I will be in Tokyo February 16–17. Would a brief meeting be useful? Zoom works too if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Toshiaki Nagasato,toshiaki.nagasato@meiji.com,Meiji Seika Kaisha Ltd,Reducing Manual Screening for External Assets,"Dear Nagasato-san,

With Meiji Seika’s MBC BioLabs partnership driving the company’s open innovation strategy, your Bioscience Labs team may be seeing a growing number of external asset candidates to evaluate.

Preparing structured assessments for each one — reviewing documents, extracting data, writing up analysis — is essential work, but it can be slow when done manually.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Structured data extraction and standardized evaluation
- Risk/gap analysis and auto-generated Decision Packs
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17. Could we meet for 30 minutes to discuss whether this fits your lab’s evaluation process? Zoom works too if in-person is difficult.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hiroyuki Hayashi,hiroyuki.hayashi@meiji.com,Meiji Seika Kaisha Ltd,Structured Screening for Open Innovation Candidates,"Dear Hayashi-san,

With Meiji Seika’s open innovation strategy gaining momentum — notably through the MBC BioLabs partnership — the evaluation pipeline flowing through your Research Institute is likely expanding.

Having a structured, repeatable way to screen incoming candidates can make a meaningful difference as that volume grows.

Our In-Licensing Workflow AI is designed to support that by automating key steps:

- Structured data extraction and standardized evaluation from source documents
- Risk analysis and auto-generated Decision Packs
- On-premise deployment with full audit trail and governance compliance

I will be in Tokyo February 16–17. Could we find 30 minutes to meet? Zoom also works if in-person is not possible.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hirotake Ishida,hirotake.ishida@raqualia.com,RaQualia Pharma Inc,Automating Candidate Evaluation at RaQualia,"Dear Ishida-san,

With tegoprazan’s FDA filing underway as of January 2026, RaQualia’s pace of activity across the pipeline is picking up. For the Drug Discovery Innovation Group, that likely means more asset candidates to evaluate alongside ongoing work.

Preparing structured assessments for each candidate — pulling data from multiple sources, analyzing fit, writing up findings — takes time when done manually.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Structured data extraction and evaluation analysis
- Risk/gap analysis and Decision Pack generation
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17 and would welcome a meeting. Zoom also works if that is more convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kiyoshi Kawamura,kiyoshi.kawamura@raqualia.com,RaQualia Pharma Inc,Reducing Licensing Screening Workload at RaQualia,"Dear Kawamura-san,

With tegoprazan’s FDA filing underway, RaQualia is entering a busy phase. As VP of R&D, you may be evaluating a growing number of licensing opportunities on both the in-licensing and out-licensing sides.

Our In-Licensing Workflow AI is designed to reduce the manual workload in that process by automating key steps:

- Document organization and structured data extraction
- Risk/gap analysis and Decision Pack generation
- On-premise deployment with built-in audit trail and governance compliance

I will be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if in-person timing does not line up.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Toshiyuki Saito,toshiyuki.saito@raqualia.com,RaQualia Pharma Inc,AI for BD Evaluation Workflows at RaQualia,"Dear Saito-san,

As VP of BD & IP at RaQualia, you are managing both out-licensing of proprietary assets and evaluation of incoming opportunities — with tegoprazan’s FDA filing adding momentum to an already active period.

Each deal requires assembling evaluation documents, extracting IP-relevant data, and building decision materials for stakeholders. That process can become a bottleneck as volume grows.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Document extraction and structured evaluation analysis
- Decision Pack generation with built-in audit trail
- On-premise deployment with governance compliance

I will be in Tokyo February 16–17. Could we find 30 minutes to meet? Zoom works well too if in-person is not feasible.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yusuke Ohno,yusuke.ohno@raqualia.com,RaQualia Pharma Inc,Faster Asset Screening for Research Planning,"Dear Ohno-san,

With tegoprazan’s FDA filing underway and RaQualia’s pipeline progressing, your research planning work likely involves evaluating which new opportunities to pursue next.

That process — reviewing documents, organizing data, building assessment reports — works, but it is time-consuming when done manually for each candidate.

Our In-Licensing Workflow AI is designed to reduce that workload by automating key steps:

- Structured data extraction and standardized evaluation
- Risk/gap analysis and Decision Pack generation
- On-premise deployment with full audit trail

I will be in Tokyo February 16–17 and would welcome a meeting if your schedule allows. Zoom is also an option.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Annamaria Muroni,annamaria@nl.jcrpharm.com,JCR Pharmaceuticals,Licensing evaluation support for JCR's clinical ops,"Dear Muroni-san,

I noticed JCR's recent partnership with Acumen on the Alzheimer's program — that kind of deal naturally adds evaluation workload for the clinical operations side.

When licensing activity picks up, teams often spend a large share of their time pulling documents from different sources, organizing clinical data, and assembling evaluation materials before any real analysis begins.

Our In-Licensing Workflow AI is designed to help reduce that early-stage workload:

- Extracts and structures data from candidate documents automatically
- Generates standardized evaluation summaries and Decision Packs
- Runs fully on-premise with audit trail for governance compliance

I'll be in Tokyo February 16–17. Would a 30-minute meeting work? Zoom is also fine if timing is easier that way.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masaaki Usui,usui-m@jp.jcrpharm.com,JCR Pharmaceuticals,Supporting JCR's licensing evaluation workflow,"Dear Usui-san,

JCR's partnership with Acumen on the Alzheimer's program reflects a clear move toward expanding the global licensing portfolio — which typically means more cross-border opportunities to evaluate on the operations side.

As that volume grows, the work of reviewing candidate documents, extracting key data points, and preparing evaluation materials for decision-makers can become a recurring bottleneck.

Our In-Licensing Workflow AI is designed to help reduce that workload:

- Automates key steps in document extraction and candidate evaluation
- Produces standardized Decision Packs with risk and gap analysis
- Deploys on-premise with full audit trail

I'll be in Tokyo February 16–17 and would welcome a 30-minute meeting. Zoom is also available if that works better.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ryo Wakita,wakita-r@jp.jcrpharm.com,JCR Pharmaceuticals,Reducing evaluation prep time for JCR's clinical team,"Dear Wakita-san,

With JCR's recent Acumen partnership adding to the licensed-in portfolio, I expect clinical trial management teams are handling evaluation work alongside ongoing trial responsibilities.

In practice, that often means pulling data from multiple sources, organizing documents, and building evaluation reports manually — time that could otherwise go toward trial execution.

Our In-Licensing Workflow AI is designed to help reduce that preparation workload:

- Extracts structured data from candidate documents automatically
- Generates standardized evaluation reports and Decision Packs
- Runs on-premise with full audit trail

I'll be in Tokyo February 16–17. Would a brief meeting work? Zoom is also available if scheduling is easier that way.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Anne Bechet,anne@nl.jcrpharm.com,JCR Pharmaceuticals,Helping JCR's clinical team with evaluation workload,"Dear Bechet-san,

JCR's recent Acumen Alzheimer's partnership signals continued growth in the licensed-in portfolio, which typically means more candidates for clinical teams to evaluate across therapeutic areas.

As that pipeline grows, the manual work of screening candidates — reviewing documents, organizing data, and preparing decision materials — can slow down how quickly the team moves on new opportunities.

Our In-Licensing Workflow AI is designed to help reduce that screening workload:

- Automates document extraction and structures candidate data
- Generates Decision Packs with risk and gap analysis
- Deploys fully on-premise with audit trail and governance compliance

I'll be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if that's more convenient.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Karina Andrade,karina@jcrpharm.com.br,JCR Pharmaceuticals,Evaluation support for JCR's regional BD work,"Dear Andrade-san,

JCR's Acumen partnership reflects the company's expanding global licensing reach, which likely means more cross-border opportunities for your regional BD team to evaluate — each with its own regulatory and market context.

Assembling evaluation materials across different geographies typically involves pulling together documents from varied sources, extracting relevant data, and building decision-ready materials. That process can be time-consuming when done manually for each market.

Our In-Licensing Workflow AI is designed to help reduce that effort:

- Automates key steps in document extraction and candidate evaluation
- Produces standardized Decision Packs with risk and gap analysis
- Runs on-premise with full audit trail and governance compliance

I'll be in Tokyo February 16–17. Would a 30-minute meeting work? If in-person isn't feasible given geography, Zoom is equally fine.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Michael Orsini,michael_orsini@eisai.com,Eisai,EEG-based responder prediction for AD trials,"Dear Orsini-san,

With the subcutaneous formulation of LEQEMBI now approved, I expect your clinical development team is looking at ways to identify likely responders earlier in the trial process.

Currently, responder identification in AD trials relies heavily on cognitive scales that take months to show meaningful separation. Adding an objective biomarker layer could help shorten that feedback loop.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI to predict drug responder status, providing quantifiable biomarker data earlier than traditional cognitive endpoints:

- Generates automated research briefs from EEG analysis
- Uses a standardized analysis pipeline across studies
- Deploys fully on-premise — no data leaves your environment

I'll be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if that's more convenient.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Helena Heanue-Travers,helena_heanue-travers@eisai.com,Eisai Co. Ltd.,EEG-Based Biomarkers for CNS Trial Operations,"Hi Helena,

With LEQEMBI now approved across multiple markets, Eisai's clinical operations teams are likely managing an increasing volume of CNS trial data with subjective endpoints.

In CNS trials, responder analysis often depends on clinical rating scales that can be difficult to standardize across sites. Our Neuro-Biomarker Co-Scientist is designed to help with this by offering:

- EEG-based AI for early responder stratification, providing an objective layer alongside traditional endpoints
- A standardized analysis pipeline with auto-generated research briefs for internal review
- Fully on-premise deployment with no external data transfer

I will be in Tokyo on Feb 16-17. Would you have 30 minutes to meet? Zoom works as well if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Gregory Seminack,gregory_seminack@eisai.com,Eisai Co. Ltd.,Reducing Late-Stage CNS Trial Risk with Biomarker AI,"Hi Gregory,

With Eisai investing in evenamide Phase 3 alongside ongoing LEQEMBI commercialization, R&D finance is likely closely evaluating where trial spend delivers the best return.

One area where cost overruns tend to occur is patient stratification in CNS trials -- late-stage failures linked to poorly defined responder populations can be costly. Our Neuro-Biomarker Co-Scientist is designed to help address this:

- EEG-based AI for early responder identification, supporting earlier go/no-go decisions
- Auto-generated research briefs for streamlined internal review
- Fully on-premise deployment -- no vendor data access

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss how this might relate to Eisai's R&D budget planning? Zoom is also an option if in-person does not work.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ali Ardati,ali_ardati@eisai.com,Eisai,Objective biomarker data for Eisai's CNS pipeline,"Dear Ardati-san,

With evenamide entering Phase 3 in Japan, Eisai's CNS pipeline continues to grow — and with it, the need for objective biomarker evidence to complement subjective clinical scales.

Traditional cognitive endpoints take time to mature, which can slow development decisions. An EEG-based biomarker approach offers a way to generate quantifiable responder data earlier in that process.

Our Neuro-Biomarker Co-Scientist uses EEG-AI to predict responder versus non-responder status:

- Runs a standardized analysis pipeline across studies
- Auto-generates research briefs ready for internal review
- Deploys fully on-premise — no data leaves your environment

I'll be in Tokyo February 16–17. Could we find 30 minutes to meet? Zoom also works if in-person is difficult.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Pooja Gaikwad,pooja_gaikwad@eisai.com,Eisai,On-premise AI for Eisai's CNS biomarker analysis,"Dear Gaikwad-san,

As Eisai expands LEQEMBI across multiple markets, R&D IT teams face a familiar tension: enabling AI-driven analysis tools while maintaining strict control over sensitive patient data.

Our Neuro-Biomarker Co-Scientist was designed with that constraint in mind:

- Uses EEG-based AI to predict drug responder status
- Runs a standardized analysis pipeline with automated research brief generation
- Deploys fully on-premise — no cloud dependency, no external data transfer

The platform is built to fit within existing IT governance frameworks rather than requiring exceptions to them.

I'll be in Tokyo February 16–17. Would a 30-minute meeting work to discuss how this fits your R&D IT architecture? Zoom is also fine.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
June Nguyen,june_nguyen@eisai.com,Eisai,Biomarker tools for Eisai's CNS business development,"Dear Nguyen-san,

Eisai's BioArctic partnership on lecanemab reflects a strong commitment to neuroscience — and partnerships like that often benefit from objective, data-driven evidence when evaluating pipeline assets and shaping development narratives.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI to predict drug responder status, providing quantifiable biomarker data that can support both internal development decisions and partnership discussions:

- Auto-generates research briefs from standardized EEG analysis
- Deploys on-premise — data stays within your environment

I'll be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if scheduling is tight.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Nandan Shah,nandan_shah@eisai.com,Eisai Co. Ltd.,On-Premise EEG-AI Platform for R&D IT Review,"Hi Nandan,

As Eisai's CNS portfolio expands globally, R&D IT teams are likely receiving more requests for AI-powered analytics tools -- while also needing to maintain strict data governance.

Our Neuro-Biomarker Co-Scientist was built with that balance in mind:

- EEG-based AI for drug responder stratification, designed to support CNS trial teams
- Fully on-premise deployment -- no cloud dependency, no external data transfer
- Standardized analysis pipeline with auto-generated research briefs

I will be in Tokyo on Feb 16-17. Would 30 minutes work to walk through the architecture and discuss how it fits within Eisai's R&D IT environment? Zoom is also fine if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Daisuke Ito,d-ito@hhc.eisai.co.jp,Eisai Co. Ltd.,脳波AIによるCNS開発支援のご提案,"伊藤様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

エーザイ様はLEQEMBI皮下注の承認をはじめ、CNS領域の開発を精力的に推進されていると拝察いたします。

弊社のNeuro-Biomarker Co-Scientistは、脳波（EEG）ベースのAIによりレスポンダーの早期特定を支援し、治療効果の客観的な定量化を支援いたします。オンプレミス導入のため、データが外部に出ない設計です。

2月16〜17日に東京におりますので、30分ほどお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
John Petrera,john_petrera@eisai.com,Eisai,Earlier responder identification in AD trials,"Dear Petrera-san,

In Eisai's AD trials, identifying LEQEMBI responders currently relies on cognitive scales that take months to show separation — and ARIA monitoring adds another layer of complexity to clinical project management.

An EEG-based biomarker approach can help by providing earlier, objective responder data before those traditional endpoints mature.

Our Neuro-Biomarker Co-Scientist is designed for this:

- Uses EEG-AI to predict responder versus non-responder status
- Generates standardized research briefs for project reviews
- Deploys fully on-premise — no data exposure

I'll be in Tokyo February 16–17. Could we meet for 30 minutes? Zoom also works if that's easier.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yoshitaka Maeda,yoshitaka_maeda@eisai.com,Eisai Co. Ltd.,Biomarker Capabilities for CNS Partnership Discussions,"Hi Yoshitaka,

With Eisai's LEQEMBI partnership model continuing to expand -- including the recent China BLA filing -- BD teams may be considering what differentiated capabilities can strengthen the next wave of CNS collaborations.

Objective biomarker data is one area that can add value to both internal pipeline evaluation and partnership discussions. Our Neuro-Biomarker Co-Scientist offers:

- EEG-based AI designed for drug responder stratification, providing an objective data layer
- Auto-generated research briefs for faster internal and partner-facing review
- Fully on-premise deployment -- no external data access

I will be in Tokyo on Feb 16-17. Would 30 minutes work to explore whether this could be relevant to Eisai's BD strategy? Zoom is fine if in-person does not work.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Osamu Kikuchi,osamu_kikuchi@eisai.com,Eisai Co. Ltd.,Scalable Biomarker Tools for CNS R&D Teams,"Hi Osamu,

As Eisai's CNS programs grow globally, R&D teams are working with increasingly complex biomarker data. Building internal capacity to interpret EEG-based evidence at scale is a meaningful undertaking.

Our Neuro-Biomarker Co-Scientist is designed to make that more practical:

- EEG-based AI for drug responder stratification, with a standardized analysis pipeline
- Auto-generated research briefs that make biomarker insights accessible to broader team members
- Fully on-premise deployment -- no external data concerns

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss how this might support R&D capability building at Eisai? Zoom also works if in-person is not convenient.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kentaro Nagane,kentaro_nagane@eisai.com,Eisai Co. Ltd.,Biomarker Infrastructure for CNS Portfolio Planning,"Hi Kentaro,

With Eisai's corporate strategy centered on CNS -- and LEQEMBI subcutaneous formulation now approved -- planning teams are likely evaluating which emerging technologies can support sustained portfolio growth.

One area worth considering is objective biomarker infrastructure for reducing late-stage trial risk. Our Neuro-Biomarker Co-Scientist offers:

- EEG-based AI designed for drug responder stratification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment with full audit trail

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss whether this is relevant to Eisai's longer-term CNS planning? Zoom works as well if in-person is not feasible.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Jason Lo,jason_lo@eisai.com,Eisai Co. Ltd.,Objective Biomarker Data for CNS Differentiation,"Hi Jason,

With LEQEMBI now approved as a subcutaneous formulation, Eisai has a strong position in the AD market. As competition in this space grows, demonstrating objective, measurable treatment differentiation will likely become increasingly important.

Our Neuro-Biomarker Co-Scientist is designed to help generate that kind of evidence:

- EEG-based AI for drug responder stratification, producing objective biomarker data
- Auto-generated research briefs that can support both regulatory and commercial narratives
- Fully on-premise deployment -- no external data exposure

I will be in Tokyo on Feb 16-17. Would 30 minutes work to explore whether this could support Eisai's marketing and BD efforts? Zoom is an option if in-person does not work.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Mary Ellen,msodano@eisai.com,Eisai,Biomarker summaries for Eisai's medical affairs reviews,"Dear Mary Ellen-san,

With LEQEMBI post-marketing evidence growing and evenamide Phase 3 data coming in, medical affairs teams at Eisai are likely spending more time turning biomarker data into review-ready summaries.

That preparation step — organizing raw data into structured, interpretable formats — can take up a meaningful share of the review cycle.

Our Neuro-Biomarker Co-Scientist is designed to help reduce that effort:

- Auto-generates standardized research briefs from EEG-based AI analysis
- Uses a consistent analysis pipeline across studies
- Runs fully on-premise — data stays within Eisai's environment

I'll be in Tokyo February 16–17. Could we meet for 30 minutes to discuss how this might fit your planning workflows? Zoom is also fine.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hassan Naqvi,hassan_naqvi@eisai.com,Eisai,On-premise EEG-AI platform — technical overview for Eisai,"Dear Naqvi-san,

As Eisai scales its CNS pipeline across multiple geographies, the systems team is likely evaluating how to bring in AI tools without introducing new security or compliance risks.

Our Neuro-Biomarker Co-Scientist was built with that concern in mind:

- Uses EEG-based AI to predict drug responder status
- Runs a standardized analysis pipeline with automated research brief generation
- Deploys fully on-premise — no cloud, no external data transfer

The architecture is designed to integrate within existing infrastructure rather than requiring new data governance exceptions.

I'll be in Tokyo February 16–17. Would 30 minutes work to walk through the technical architecture? Zoom also works if in-person is difficult.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Shamara Karunaratne,shamara_karunaratne@eisai.com,Eisai,Adoption-ready biomarker AI for Eisai's R&D teams,"Dear Karunaratne-san,

As Eisai's CNS pipeline grows, R&D teams will likely need to adopt new analytical tools — but in pharma, new platforms can be difficult to roll out when outputs aren't standardized or easy to interpret.

Our Neuro-Biomarker Co-Scientist was designed with adoption in mind:

- Uses EEG-based AI to predict drug responder status
- Runs a standardized pipeline and auto-generates plain-language research briefs
- Deploys on-premise, so no new data governance requirements are introduced

The goal is to give R&D teams a tool they can actually use without a steep onboarding curve.

I'll be in Tokyo February 16–17. Could we meet for 30 minutes to discuss how this fits Eisai's approach to new tool adoption? Zoom also works.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Andrew Pachuta,andrew_pachuta@eisai.com,Eisai,Earlier responder data for Eisai's AD projects,"Dear Pachuta-san,

With LEQEMBI SC now approved and ARIA monitoring adding complexity to AD trial management, decisions about patient stratification directly affect project timelines.

Currently, responder identification relies on cognitive scales that take months to mature. An EEG-based biomarker approach can provide earlier, objective data to support those decisions.

Our Neuro-Biomarker Co-Scientist is designed for this:

- Uses EEG-AI to predict drug responder status before cognitive endpoints mature
- Runs a standardized pipeline with automated research brief generation
- Deploys fully on-premise — no data exposure

I'll be in Tokyo February 16–17. Could we find 30 minutes to discuss how this applies to your AD projects? Zoom also works if in-person is difficult.

If I'm not the right contact for this, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hiroyuki Muramatsu,h-muramatsu@hhc.eisai.co.jp,Eisai Co. Ltd.,東アジアCNS事業向け脳波AIのご提案,"村松様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

中国でのBLA申請完了を踏まえ、東アジア・グローバルサウスにおけるエーザイ様のCNS事業は新たな局面を迎えていらっしゃるかと存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIにより薬剤応答者の層別化を支援するプラットフォームです。治療効果の客観的な定量化にも寄与し、オンプレミス導入のためデータが外部に出ない設計です。

2月16〜17日に東京におります。30分ほどお時間をいただき、東アジア地域でのCNS開発への活用についてご相談できればと存じます。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Sara Pena Martinez,sara_pena@eisai.com,Eisai Co. Ltd.,Objective Biomarker Evidence for CNS Marketing,"Hi Sara,

Marketing CNS therapies often means building narratives around subjective cognitive scales, which can make it harder to differentiate in a competitive market -- especially as LEQEMBI faces increasing competition in the AD space.

Objective biomarker evidence showing which patients respond could help strengthen those narratives. Our Neuro-Biomarker Co-Scientist is designed to provide that:

- EEG-based AI for drug responder stratification, generating objective data points
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no data exposure

I will be in Tokyo on Feb 16-17. Would 30 minutes work to explore whether this could support your CNS marketing strategy? Zoom is also fine.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yoshimi Kuroiwa,kuroiwa.yoshimi@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,精神・神経領域向け脳波AIのご提案,"黒岩様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様は精神・神経領域がパイプラインの最重点カテゴリーであり、centanafadine（ADHD）のPDUFA 2026年7月など重要な開発マイルストーンが続いていると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIにより薬剤応答者の層別化を支援し、治療効果の客観的な定量化に寄与いたします。標準化された解析パイプラインと自動レポート生成により、社内レビューの効率化も支援いたします。

オンプレミス導入のため、データが外部に出ない設計です。

2月16〜17日に東京におります。30分ほどお打ち合わせのお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Bernadette Donohue,bernadette_donohue@mt-pharma-us.com,Otsuka Pharmaceutical,On-Premise Biomarker AI for CNS Clinical Sourcing,"Hi Bernadette,

With centanafadine targeting a PDUFA date in July 2026, Otsuka's clinical development sourcing team is likely evaluating tools that can support CNS trial execution without adding unnecessary complexity.

Our Neuro-Biomarker Co-Scientist is an EEG-based AI platform designed for that purpose:

- Responder stratification to support earlier decision-making in CNS trials
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no vendor data access

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to walk through how this might fit Otsuka's sourcing criteria? Zoom also works.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Michael Krause,michaelk@otsuka-us.com,Otsuka Pharmaceutical,EEG-Based Biomarkers for CNS Project Decisions,"Hi Michael,

Managing CNS projects at Otsuka with centanafadine targeting PDUFA in July 2026 means navigating go/no-go decisions that often rely on subjective psychiatric endpoints.

Our Neuro-Biomarker Co-Scientist is designed to add an objective layer to that process:

- EEG-based AI for early responder identification in CNS trials
- Auto-generated research briefs for project review meetings
- Fully on-premise deployment -- no external data transfer

I will be in Tokyo on Feb 16-17. Would 30 minutes work to discuss? Zoom is also fine.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Masahiro Kajita,kajita.masahiro@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,精神・神経パイプライン向け応答者層別化AIのご提案,"梶田様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様はulotarontの完全自社化やcentanafadineのPDUFA（2026年7月）など、精神・神経領域のパイプラインを積極的に拡充されていると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIによりレスポンダーの早期特定を支援し、治療効果の客観的な定量化に寄与するプラットフォームです。オンプレミス導入のため、データが外部に出ない設計です。

2月16〜17日に東京におりますので、30分ほどお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Philomene Akafack,philomene.akafack@otsuka-us.com,Otsuka Pharmaceutical,Earlier Signals for CNS Trial Decisions,"Hi Philomene,

With psychiatry and neurology as Otsuka's leading pipeline category, project managers across these programs often face the same challenge: psychiatric endpoints are inherently subjective, which can make responder analysis time-consuming.

Our Neuro-Biomarker Co-Scientist is designed to help by providing an objective complement to traditional scales:

- EEG-based AI for early responder stratification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no data leaves your network

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss? Zoom works as well.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Janelle Burnham,janelle.burnham@otsuka-us.com,Otsuka Pharmaceutical Co. Ltd.,Objective Biomarkers for Otsuka's CNS Clinical Programs,"Hi Janelle,

With psychiatry and neurology as Otsuka's leading pipeline category, clinical development teams working on these programs may benefit from biomarker tools that go beyond subjective rating scales.

Our Neuro-Biomarker Co-Scientist is designed to support that:

- EEG-based AI for responder stratification, offering an objective biomarker layer for CNS trials
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no external data transfer

I will be in Tokyo on Feb 16-17. Would 30 minutes work to discuss whether this could be relevant to Otsuka's clinical development programs? Zoom is fine if in-person does not work.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Thomas Thompson,thomas.thompson@otsuka-us.com,Otsuka Pharmaceutical,EEG-Based Biomarker Platform for Otsuka's CNS Portfolio,"Hi Thomas,

With centanafadine heading toward a PDUFA date in July 2026, Otsuka's CNS portfolio is at a critical stage. Across psychiatry and neurology programs, one recurring difficulty is that psychiatric endpoints are subjective, which can make responder identification slower than it needs to be.

Our Neuro-Biomarker Co-Scientist is designed to provide an objective complement:

- EEG-based AI for drug responder stratification across CNS indications
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no data leaves your network

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss where objective biomarker tools might fit across Otsuka's CNS programs? Zoom works if in-person is not possible.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Hitomi Kawaguchi,kawaguchi.hitomi@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,臨床開発計画向け脳波AIバイオマーカーのご提案,"川口様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様では精神・神経領域がパイプラインの最重点カテゴリーであり、centanafadine（PDUFA 2026年7月）をはじめ臨床開発計画の重要な局面にあると拝察いたします。

精神科領域では、主観的評価尺度に依存した応答者特定が課題の一つかと存じます。弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIにより応答者の層別化を支援し、治療効果の客観的な定量化に寄与いたします。

オンプレミスで導入でき、自動レポート生成機能も備えております。

2月16〜17日に東京におります。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Mohit Patel,mohit.patel@otsukapharma.in,Otsuka Pharmaceutical Co. Ltd.,Biomarker Tools for CNS Business Development,"Hi Mohit,

With psychiatry and neurology as Otsuka's leading pipeline category, BD teams evaluating and positioning these assets may benefit from objective biomarker data beyond traditional subjective scales.

Our Neuro-Biomarker Co-Scientist is designed to support that kind of evaluation:

- EEG-based AI for drug responder stratification, producing quantifiable biomarker evidence
- Auto-generated research briefs for streamlined internal review
- Fully on-premise deployment -- no data exposure

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to explore whether this is relevant to Otsuka's BD priorities? Zoom works if in-person is difficult.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kazuto Yamada,yamada.kazuto@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,臨床開発効率化に向けた脳波AIのご提案,"山田様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様にて臨床開発計画の統括および複数のR&D機能を監督されている山田様に、精神・神経領域の開発効率化を支援する取り組みについてご提案させていただきたくご連絡いたしました。

centanafadine（PDUFA 2026年7月）をはじめ複数の重要プログラムが同時に進行する中、客観的バイオマーカーによる応答者特定が開発効率の鍵になると拝察いたします。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIによりレスポンダーの早期特定を支援いたします。標準化された解析パイプラインと自動レポート生成機能を備え、オンプレミスで導入可能です。

2月16〜17日に東京にてお打ち合わせのお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Iku Nakayama,nakayama.iku@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,オンプレミス対応の脳波AI解析基盤のご提案,"中山様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様のデジタルビジネス推進室では、臨床開発領域のデジタル化においてデータセキュリティとQMS要件の両立が重要な課題かと存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIにより薬剤応答者の層別化を支援するプラットフォームです。完全オンプレミス導入のためデータが外部に出ず、標準化された解析パイプラインはQMS要件との整合性を取りやすい設計としております。

2月16〜17日に東京におります。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yoshitaka Kotobuki,kotobuki.yoshitaka@otsuka.jp,Otsuka Pharmaceutical Co. Ltd.,少人数R&Dチーム向け脳波AI解析のご提案,"寿様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

大塚製薬様のSmall Global R&D部門では、限られたリソースの中で精神・神経領域の重要な開発を推進されていると拝察いたします。

少人数チームでは、バイオマーカー解析からレビュー資料作成まで手作業の負荷が大きくなりがちかと存じます。弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIにより応答者の層別化を支援し、標準化パイプラインと自動レポート生成で解析業務の効率化に寄与いたします。

オンプレミス導入のため、データ管理の面でもご安心いただける設計です。

2月16〜17日に東京におります。30分ほどお打ち合わせのお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Saki Sakurai,saki.sakurai@sumitomo-pharma.co.jp,Sumitomo Pharma Co. Ltd.,CNS臨床研究における脳波解析のご提案,"櫻井様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はCNS営業部を独立組織として維持されており、CNS領域の臨床研究基盤を引き続き大切にされているものと拝察いたします。

臨床研究において、薬剤応答者の早期特定は試験効率を左右する重要課題かと存じます。弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIで応答者の早期特定を支援するプラットフォームです。

標準化された解析パイプラインと自動レポート生成機能を備えており、オンプレミス導入にも対応しております。

2月16〜17日に東京におりますので、お時間をいただけるようでしたらお打ち合わせの機会を頂ければ幸いです。Zoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Cristian Nita,cristian.nita@urovant.com,Sumitomo Pharma,EEG Biomarker AI for CNS Project Management,"Hi Cristian,

With Sumitomo Pharma's portfolio evolving, any current or future CNS programs could benefit from objective biomarker tools that go beyond traditional subjective endpoints.

Our Neuro-Biomarker Co-Scientist is designed to support CNS project teams in that area:

- EEG-based AI for drug responder stratification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment -- no external data transfer

I will be in Tokyo on Feb 16-17. Could we find 30 minutes to discuss whether this might be relevant? Zoom also works.

If I am not the right contact for this, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Shunichiro Uesugi,shunichiro.uesugi@sumitomo-pharma.co.jp,Sumitomo Pharma Co. Ltd.,CNS資産を活かすR&D戦略のご提案,"上杉様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はオンコロジー・再生医療へのシフトを進められる一方、CNS営業部を独立組織として維持されており、CNS領域の商業基盤は貴重な資産かと存じます。

このCNS基盤をさらに活用いただく一助として、弊社のNeuro-Biomarker Co-Scientistをご紹介させていただければと思います。脳波ベースのAIでレスポンダーの層別化を支援するプラットフォームです。

標準化された解析パイプラインと自動レポート生成機能を備え、オンプレミス導入にも対応しております。

2月16〜17日に東京におりますので、お打ち合わせの機会を頂ければ幸いです。Zoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Shogo Shibata,shogo.shibata@sumitomo-pharma.co.jp,Sumitomo Pharma Co. Ltd.,CNSマーケティングにおける客観的エビデンスのご提案,"柴田様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はCNS営業部を独立組織として維持されており、柴田様はCNS製品マーケティングのシニアディレクターとして、この領域の商業価値をさらに発展させるお立場にいらっしゃると拝察いたします。

CNS製品のマーケティングにおいて、主観的評価尺度のみでは差別化が難しい場面もあるかと存じます。弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIで応答者の早期特定を支援し、客観的バイオマーカーによる治療効果の定量化に寄与いたします。

オンプレミス導入にも対応しておりますので、データ管理面でもご安心いただけるかと存じます。

2月16〜17日に東京におります。30分ほどお打ち合わせのお時間をいただけますでしょうか。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Tomoko Goda,tomoko.goda@sumitomo-pharma.co.jp,Sumitomo Pharma Co. Ltd.,CNS提携における脳波AIプラットフォームのご提案,"合田様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はulotarontの大塚製薬への移管後もCNS営業部を独立維持されており、今後の提携戦略において差別化できる技術基盤が重要になるかと存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの層別化を支援するプラットフォームです。客観的バイオマーカーによる治療効果の定量化や、標準化パイプラインによる自動レポート生成にも対応しております。

オンプレミス導入が可能ですので、提携先とのデータ管理面でもご活用いただけるかと存じます。

2月16〜17日に東京におりますので、お打ち合わせの機会を頂ければ幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Christina Kelly,christina.tascione@takeda.com,Takeda,EEG Biomarkers for CNS Trial Efficiency,"Dear Christina,

With TAK-861 advancing through Phase 3 in narcolepsy, your team is likely preparing evidence packages for regulatory submissions. One recurring challenge in CNS programs is that subjective endpoints can delay clear go/no-go decisions.

We built the Neuro-Biomarker Co-Scientist to help with that:

- EEG-based AI designed for responder stratification and early signal identification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment with no data leaving your infrastructure

I'll be in Tokyo February 16-17 and would welcome 20 minutes to discuss whether this could be relevant. A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Shashank Shanbhag,shashank.shanbhag@takeda.com,Takeda,Objective CNS Evidence for Commercial Strategy,"Dear Shashank,

As Takeda moves toward commercialization of its orexin-based CNS portfolio, payer and HTA discussions will likely require objective efficacy evidence beyond subjective clinical scales.

We built the Neuro-Biomarker Co-Scientist with this in mind:

- EEG-based AI designed for responder stratification using quantifiable biomarker data
- Objective treatment-effect measurement that can support value dossier development
- Fully on-premise, no patient data leaves your systems

I'll be in Tokyo February 16-17 and would welcome 20 minutes to discuss how this might apply to Takeda's commercial planning. A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Charlotte Barry-Delongchamps,charlotte.barry@takeda.com,Takeda,CNS Biomarker Tools for Emerging Markets,"Dear Charlotte,

Takeda's partnership with Nabla Bio reflects a strong commitment to AI-driven innovation. As you evaluate CNS opportunities across emerging markets, objective biomarker evidence could be a useful differentiator in regulatory and partner conversations.

Our Neuro-Biomarker Co-Scientist is designed with diverse regulatory environments in mind:

- EEG-based AI for responder stratification and objective treatment-effect measurement
- Auto-generated research briefs on a standardized pipeline
- Fully on-premise with no data leaving your infrastructure

I'll be in Tokyo February 16-17. Could we find 20 minutes to explore whether this fits Takeda's emerging market BD work? A Zoom call is equally fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Antonio Toma,antonio.toma@takeda.com,Takeda,On-Premise AI for CNS Data Governance,"Dear Antonio,

As Takeda scales AI partnerships across regions, data governance and IP protection in cross-border transactions naturally become a priority — especially under European and Canadian regulatory frameworks.

Our Neuro-Biomarker Co-Scientist was built with this in mind:

- Fully on-premise EEG-based AI — no patient data leaves your infrastructure
- Designed for CNS responder stratification using objective biomarker data
- Standardized pipeline with auto-generated research briefs and full audit trail

I'll be in Tokyo February 16-17. Would 20 minutes work to discuss how this architecture could support Takeda's deal structuring? A Zoom call is equally fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Francis Fordjour,francis.fordjour@takeda.com,Takeda,Objective Signals for CNS Portfolio Decisions,"Dear Francis,

Portfolio strategy in CNS often depends on getting clear signals early — but most neuroscience programs still rely on subjective outcome measures that can obscure treatment effects until late-stage readouts.

With TAK-861 progressing through Phase 3 in narcolepsy, embedding objective biomarkers earlier in the pipeline could help inform go/no-go decisions across the portfolio. Our Neuro-Biomarker Co-Scientist is designed to support that:

- EEG-based AI for responder stratification and early signal identification
- Standardized pipeline with auto-generated research briefs
- Fully on-premise, no data leaves your infrastructure

I'll be in Tokyo February 16-17 — would either date work for a brief discussion? A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ronan Fitzgerald,ronan.fitzgerald@takeda.com,Takeda,CNS-Specific AI Platform for Research Partnerships,"Dear Ronan,

Takeda's partnership with Nabla Bio reflects a clear appetite for technology collaborations that can accelerate drug discovery. As you develop Takeda's innovation network, CNS-specific AI tools may be a useful area to explore.

Our Neuro-Biomarker Co-Scientist is built for translational neuroscience:

- EEG-based AI designed for responder stratification and objective biomarker quantification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise — no data leaves your infrastructure

I'll be in Tokyo February 16-17. Could we meet for 20 minutes to discuss whether this fits within Takeda's partnership strategy? A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Takahiro Imanaka,takahiro.imanaka@takeda.com,Takeda,Objective Biomarkers for Japan CNS Development,"Dear Takahiro,

Leading Japan development at Takeda means navigating PMDA expectations while staying aligned with global timelines. For CNS assets like TAK-861, objective efficacy data can help strengthen domestic submissions and support cross-regional consistency.

Our Neuro-Biomarker Co-Scientist is designed with Japan's requirements in mind:

- EEG-based AI for responder stratification and objective treatment-effect measurement
- Fully on-premise — all data stays within your infrastructure, supporting data residency needs
- Auto-generated research briefs to help streamline regulatory documentation

I'll be in Tokyo February 16-17 and would welcome the chance to meet in person. Would either date work? A Zoom call is also available.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Chris Hurff,chris.hurff@takeda.com,Takeda,EEG AI for CNS Research Collaborations,"Dear Chris,

Takeda's investment in orexin biology — with TAK-861 advancing through Phase 3 in narcolepsy — positions your team to explore tools that can extend this work in CNS.

One gap in many CNS research partnerships is the lack of objective, scalable biomarker platforms. Our Neuro-Biomarker Co-Scientist is designed to help address that:

- EEG-based AI for responder stratification and objective biomarker quantification
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise, no data leaves your infrastructure

I'll be in Tokyo February 16-17. Would 20 minutes work to explore whether this aligns with Takeda's research BD priorities? A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Zachary Cary,zachary.cary@takeda.com,Takeda,Objective Biomarker Data Across the CNS Portfolio,"Dear Zachary,

Takeda's partnership with Nabla Bio reflects a strong commitment to embedding AI across the pipeline. One area where objective data can add value across CNS programs is biomarker-driven responder identification — an area where most programs still rely on subjective scales.

Our Neuro-Biomarker Co-Scientist is designed to help with that:

- EEG-based AI for responder stratification and objective treatment-effect measurement
- Standardized pipeline with auto-generated research briefs
- Fully on-premise — no data leaves your infrastructure

I'll be in Tokyo February 16-17. Would 20 minutes work for a conversation? A Zoom call is equally fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Gina Cerrato,gina.cerrato@takeda.com,Takeda,Standardized CNS Biomarker Workflows,"Dear Gina,

Coordinating R&D operations across a CNS-focused portfolio — with TAK-861 advancing toward global regulatory submissions — means managing complex data workflows across teams and geographies.

Our Neuro-Biomarker Co-Scientist is designed to help reduce that operational burden:

- Standardized EEG analysis pipeline with auto-generated research briefs
- Responder stratification using objective biomarker data
- Fully on-premise, no data leaves your infrastructure

I'll be in Tokyo February 16-17. Would a brief meeting work on either date? A Zoom call is equally fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Teresa Yang,teresa.yang@takeda.com,Takeda,Objective Data for Faster CNS Decisions,"Dear Teresa,

Managing global CNS projects at Takeda — with TAK-861 entering regulatory submissions — means every improvement in data analysis turnaround can matter for timelines.

Subjective endpoints often delay key decisions. Our Neuro-Biomarker Co-Scientist is designed to help reduce time spent on analysis and reporting:

- EEG-based AI for responder stratification using objective biomarker data
- Standardized pipeline with auto-generated research briefs
- Fully on-premise, no data leaves your infrastructure

I'll be in Tokyo February 16-17. Would a brief meeting on either date work? A Zoom call is also fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Frank Tamburro,frank.tamburro@takeda.com,Takeda,On-Premise AI for CNS Clinical Operations,"Dear Frank,

Procuring AI tools for clinical operations at Takeda means balancing innovation with data security, vendor compliance, and cost efficiency — especially as CNS programs scale toward global submissions.

Our Neuro-Biomarker Co-Scientist is designed to simplify that evaluation:

- Fully on-premise EEG-based AI — no patient data leaves your infrastructure
- Responder stratification and objective biomarker quantification
- Standardized pipeline with auto-generated briefs, reducing reliance on external analytics vendors

I'll be in Tokyo February 16-17. Would a brief meeting work on either date? A Zoom call is also fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Barbara Mawhinney,barbara.mawhinney@takeda.com,Takeda,Objective CNS Biomarkers for European R&D,"Dear Barbara,

With TAK-861 progressing through Phase 3 in narcolepsy, European regulatory submissions will likely call for consistent, objective biomarker evidence that meets EMA expectations.

Our Neuro-Biomarker Co-Scientist is built for that kind of work:

- EEG-based AI for responder stratification and objective treatment-effect measurement
- Auto-generated standardized research briefs
- Fully on-premise with no data leaving your infrastructure, supporting GDPR-compliant data handling

I'll be in Tokyo February 16-17. Would either date work for a brief meeting? A Zoom call is also fine.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Bassem Mattar,bassem.mattar@takeda.com,Takeda,Objective CNS Biomarkers for Emerging Market Alliances,"Dear Bassem,

As Takeda expands its CNS portfolio into emerging markets following TAK-861's Phase 3 progress, having objective, reproducible biomarker data could be a useful advantage in partnership discussions.

Most CNS deals still rely on subjective clinical scales. Our Neuro-Biomarker Co-Scientist is designed to offer something different:

- EEG-based AI for responder stratification and objective biomarker quantification
- Fully on-premise — no data leaves your infrastructure, supporting varied data sovereignty requirements
- Standardized pipeline with auto-generated research briefs

I'll be in Tokyo February 16-17. Could we find 20 minutes to discuss how this might apply to Takeda's emerging market alliances? A Zoom call works just as well.

If I'm not the right contact, I'd appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Michelle McManus,michelle.mcmanus@takeda.com,Takeda,EEG-AI Biomarker Platform for CNS Teams,"Dear Michelle,

With TAK-861 advancing through Phase 3 for narcolepsy, Takeda's CNS teams will likely need new ways to work with biomarker data at scale.

We built the Neuro-Biomarker Co-Scientist to help translational teams move faster on EEG-based analysis. It is designed to:

- Predict drug responders vs. non-responders using objective EEG biomarkers
- Auto-generate standardized research briefs, reducing manual analysis steps
- Run fully on-premise with zero data leaving your environment

I will be in Tokyo on February 16-17 and would welcome 20 minutes to discuss whether this could fit your L&D plans for translational teams. A Zoom call also works if scheduling is easier.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Leslie Cousens,leslie.cousens@takeda.com,Takeda,On-Premise EEG-AI for CNS Responder Stratification,"Dear Leslie,

Takeda's Center for External Innovation has been active in AI-driven partnerships, and I wanted to introduce a platform that may be relevant to your scouting scope.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI to help stratify drug responders and auto-generate research briefs. It is designed to:

- Provide objective biomarker quantification for responder prediction
- Deliver a standardized analysis pipeline with auto-reporting
- Deploy fully on-premise, so data never leaves your environment

I will be in Tokyo on February 16-17. Could we find 20 minutes to discuss whether this fits your external innovation criteria? A Zoom call works equally well if scheduling is tight.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Taisei Masuda,taisei.masuda@takeda.com,Takeda,EEG-AI Biomarkers for Japan CNS Strategy,"Dear Taisei,

With TAK-861 having met its Phase 3 endpoints for narcolepsy type 1, Japan regulatory planning is likely moving forward -- congratulations on this progress.

Objective responder identification can support both regulatory and commercial positioning. Our Neuro-Biomarker Co-Scientist is designed to:

- Predict drug responders using EEG-based AI biomarkers
- Quantify treatment effects through a standardized pipeline
- Run entirely on-premise with zero data leakage

I will be in Tokyo on February 16-17. Would you have time for a brief meeting to discuss how this could support your Japan CNS strategy? Zoom is also available if preferred.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Nancy Mastrangelo,nancy.blanchard1@takeda.com,Takeda,On-Premise Biomarker AI for Patient Safety Data Governance,"Dear Nancy,

Given your role overseeing vendor management and alliance partnerships within Patient Safety, data governance is likely a key consideration for any new tool Takeda evaluates.

Our Neuro-Biomarker Co-Scientist is an EEG-based AI platform designed to predict drug responders and auto-generate research briefs. It is built with data security as a core requirement:

- Deploys entirely on-premise -- zero patient data leaves your infrastructure
- Provides a standardized analysis pipeline with full audit trail
- Designed to help reduce time spent on manual biomarker analysis

I will be in Tokyo on February 16-17. Could we meet briefly to discuss vendor fit for CNS programs? A Zoom call also works if that is more convenient.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Eric Yeung,eric.yeung@takeda.com,Takeda,EEG-AI for Rare CNS Patient Stratification,"Dear Eric,

Takeda's rare disease portfolio continues to grow, and computational tools are clearly part of the BD strategy going forward.

In rare neurological diseases, patient stratification carries especially high stakes. Our Neuro-Biomarker Co-Scientist is designed to help with this:

- Uses EEG-based AI to predict drug responders with objective biomarkers
- Quantifies treatment effects through a standardized pipeline
- Runs fully on-premise, so data governance is built in

I will be in Tokyo on February 16-17. Would you have 20 minutes for a meeting to discuss relevance to your rare disease programs? Zoom works equally well if schedules are tight.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Kae Matsuda,kae.matsuda@takeda.com,Takeda,Biomarker AI for Japan R&D Planning,"Dear Kae,

With TAK-861 having achieved its Phase 3 endpoints and global regulatory submissions underway, the Japan R&D strategy office is guiding a significant CNS launch period.

Objective biomarker data can support both regulatory positioning and clinical evidence planning. Our Neuro-Biomarker Co-Scientist is designed to:

- Predict drug responders using EEG-based AI
- Auto-generate standardized research briefs
- Run entirely on-premise with no data leakage

I will be in Tokyo on February 16-17. Would you have time for a brief meeting to explore how this supports Japan R&D planning? A Zoom call is also an option if preferred.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ploy Rainville,nahathai.rainville@takeda.com,Takeda,EEG-AI Platform for CNS Portfolio Strategy,"Dear Ploy,

With TAK-861 having met all Phase 3 endpoints for narcolepsy and global submissions now underway, Takeda's CNS strategy is entering a pivotal execution phase.

Our Neuro-Biomarker Co-Scientist is an EEG-based AI platform designed to support portfolio decision-making with objective data:

- Predicts drug responders using quantified EEG biomarkers
- Auto-generates research briefs through a standardized pipeline
- Deploys on-premise for complete data security

I will be in Tokyo on February 16-17. Would either date work for a 20-minute meeting to discuss strategic fit? Zoom is also available if more convenient.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Shamira Shariffudin,shamira.shariffudin@takeda.com,Takeda,EEG-Based Responder Prediction for BD Evaluation,"Dear Shamira,

As Takeda's CNS strategy advances with TAK-861 moving toward global submissions, evaluating complementary technologies is a natural part of the BD process.

One area where we see room for better tooling is objective, EEG-based drug-response prediction. Our Neuro-Biomarker Co-Scientist is designed to:

- Identify responders vs. non-responders using EEG-AI biomarkers
- Auto-generate research briefs through a standardized pipeline
- Deploy fully on-premise, with data governance built in

I will be in Tokyo on February 16-17. Could we schedule a brief meeting? Zoom also works well if preferred.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Jen Rice,jen.rice@takeda.com,Takeda,Neuro-Biomarker AI for GI Programs with CNS-Adjacent Endpoints,"Dear Jen,

Takeda's GI franchise is well-established, and as evidence around the gut-brain axis continues to develop, neuroscience tools may become increasingly relevant to GI clinical programs.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI designed to:

- Predict drug responders and quantify treatment effects with objective biomarkers
- Auto-generate standardized research briefs
- Deploy on-premise with zero data leakage

For GI compounds with CNS-adjacent endpoints -- such as cognitive symptoms in IBD -- this could help build differentiated clinical evidence.

I will be in Tokyo on February 16-17. Would you have time for a brief meeting? Zoom is also an option if more convenient.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ceri Davies,ceri.davies@takeda.com,Takeda,EEG-AI for Early CNS Candidate De-Risking,"Dear Ceri,

With TAK-861 meeting its Phase 3 endpoints, Takeda's orexin biology platform has strong momentum. As head of CNS Drug Discovery, you are well positioned to shape how the next wave of candidates is evaluated early.

Objective, translatable biomarkers remain a gap in early CNS discovery. Our Neuro-Biomarker Co-Scientist is designed to:

- Predict drug responders using EEG-based AI
- Quantify treatment effects and auto-generate research briefs
- Run fully on-premise with zero data leakage

I will be in Tokyo on February 16-17. Could we meet for 20 minutes to discuss how this fits your discovery pipeline? Zoom works equally well.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Belinda King,belinda.king@takeda.com,Takeda,Standardized EEG-AI Pipeline for Biomarker QA,"Dear Belinda,

With TAK-861 advancing toward global regulatory submissions, the need for standardized, reproducible biomarker analysis across sites will grow.

Our Neuro-Biomarker Co-Scientist is built around this requirement. It provides:

- A standardized EEG analysis pipeline with consistent outputs across sites
- Auto-generated research briefs, designed to help reduce manual analysis steps
- Fully on-premise deployment with zero data leakage and built-in audit trail

I will be in Tokyo on February 16-17. Would you have time for a brief meeting to discuss how this supports your QA workflows? A Zoom call is also available if scheduling is challenging.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Preety Mishraa,preety.mishra@takeda.com,Takeda,EEG-AI as a Digital Biomarker Tool for CNS Trials,"Dear Preety,

As project manager for Clinical Digital Device Solutions, you sit at the intersection of digital tools and clinical execution -- an area where new biomarker approaches may be relevant for Takeda's CNS programs.

Our Neuro-Biomarker Co-Scientist is an EEG-based AI platform designed to:

- Predict drug responders and generate objective biomarker data
- Integrate as a standardized pipeline for consistent trial outputs
- Run entirely on-premise, so data never leaves your systems

I will be in Tokyo on February 16-17. Would either date work for a brief meeting? A Zoom call also works at your convenience.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Charlie Alexander,charlie.alexander@takeda.com,Takeda,EEG-AI Biomarkers for Neuro-Immune Indications,"Dear Charlie,

Takeda's plasma-derived therapy franchise is a distinctive strength, and as neurological indications increasingly intersect with immunology, objective CNS biomarkers may become more relevant to your portfolio.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI designed to:

- Predict drug response and quantify treatment effects with objective biomarkers
- Auto-generate standardized research briefs
- Deploy fully on-premise with zero data leakage

For plasma-derived therapies targeting neuro-immune conditions, this could help support differentiated endpoint evidence.

I will be in Tokyo on February 16-17. Would you have time for a brief meeting? Zoom is also available at your convenience.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
John Bathery,john.bathery@takeda.com,Takeda,Biomarker AI to Support CNS BD Operations,"Dear John,

Takeda's BD operations support a broad portfolio, and with global submissions for TAK-861 now underway, the operational side of managing CNS partnerships and data continues to grow.

Our Neuro-Biomarker Co-Scientist is designed to help streamline one piece of that work:

- EEG-based AI for drug-response prediction with objective biomarkers
- Standardized analysis pipeline with auto-generated research briefs
- Fully on-premise deployment, keeping all data within your infrastructure

I will be in Tokyo on February 16-17. Could we find 20 minutes to discuss how this supports BD operations for CNS programs? Zoom is also an option.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yuki Tsushima,yuki.tsushima@sumitomo-pharma.co.jp,住友ファーマ,CNS製剤開発におけるバイオマーカー活用のご提案,"Yuki Tsushima 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はCNS販売部門を独立組織として維持されており、CNS領域への継続的な注力をされているものと拝察いたします。

弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIで薬剤レスポンダーの早期特定を支援するプラットフォームです。標準化パイプラインにより客観的バイオマーカーデータを自動生成し、解析業務の効率化に寄与いたします。

オンプレミス運用に対応しておりますので、データ管理面でもご安心いただけるかと存じます。

2月16〜17日に東京へ伺います。ご都合のよいお時間帯をお教えいただけますでしょうか。Zoomでのご面談も可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yuta Shibue,yuta.shibue@sumitomo-pharma.co.jp,住友ファーマ,R&D戦略におけるニューロバイオマーカーのご提案,"Yuta Shibue 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はオンコロジー・再生医療へのシフトを進められつつ、CNS商業基盤を維持されていると存じます。R&D戦略企画において、客観的バイオマーカーは領域横断的な意思決定の一助になるかと拝察いたします。

弊社のNeuro-Biomarker Co-Scientistは、EEGベースのAIで薬剤応答者の早期特定を支援し、解析業務の効率化に寄与いたします。オンプレミスでの運用に対応しております。

2月16〜17日に東京を訪問いたします。ご都合のよいお時間をご教示いただけますと幸いです。Zoomも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yusuke Sawayama,yusuke.sawayama@sumitomo-pharma.co.jp,住友ファーマ,グローバル経営戦略におけるAIバイオマーカーのご提案,"Yusuke Sawayama 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

住友ファーマ様はCNS販売部門を独立組織として維持され、再生医療・オンコロジーとの戦略的バランスを図られていると拝察いたします。

弊社のNeuro-Biomarker Co-Scientistは、EEGベースのAIでレスポンダーの早期特定を支援し、標準化パイプラインにより解析業務の効率化に寄与いたします。オンプレミスでの運用に対応しております。

2月16〜17日に東京へ伺います。ご面談のお時間をいただけますでしょうか。Zoomでのご説明も可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Keita Mori,keita.mori@sanbio.com,SanBio,EEG-AI Biomarkers for AKUUGO Clinical Evidence,"Dear Keita,

Congratulations on the AKUUGO approval in Japan -- a meaningful milestone for CNS regenerative medicine. With the US Phase 3 pathway now confirmed with the FDA, objective outcome measures will be important for building evidence across regulatory environments.

Our Neuro-Biomarker Co-Scientist is an EEG-based AI platform designed to:

- Predict drug responders and quantify treatment effects with objective biomarkers
- Auto-generate standardized research briefs
- Deploy on-premise, so patient data stays within your infrastructure

I will be in Tokyo on February 16-17. Would you have 20 minutes for a meeting to discuss how this could support AKUUGO's clinical evidence strategy? Zoom also works.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Ryohei Isobe,ryohei.isobe@sanbio.com,SanBio,Standardized EEG-AI for Multi-Site TBI Biomarker Analysis,"Dear Ryohei,

With AKUUGO now approved in Japan for TBI and the US Phase 3 pathway confirmed with the FDA, managing biomarker data across geographies is an increasing operational consideration.

Our Neuro-Biomarker Co-Scientist is designed to help with multi-site consistency:

- Uses EEG-based AI to predict drug responders
- Auto-generates standardized research briefs across sites
- Deploys fully on-premise with zero data leakage -- relevant for global trial coordination

I will be in Tokyo on February 16-17. Would either date work for a meeting? A Zoom call also works at your convenience.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Brian Kirshner,brian.kirshner@sanbio.com,SanBio,EEG-AI to Support SanBio's CNS Project Timelines,"Dear Brian,

With AKUUGO approved in Japan and the US Phase 3 agreement with the FDA in place, SanBio is managing multiple critical milestones in parallel. Keeping biomarker analysis efficient across these tracks matters for project timelines.

Our Neuro-Biomarker Co-Scientist is designed to help reduce time spent on manual analysis:

- EEG-based AI for drug responder prediction
- Standardized pipeline with auto-generated research briefs
- Fully on-premise with zero data leakage

I will be in Tokyo on February 16-17. Could we meet briefly to discuss how this could support your project timelines? Zoom is also an option.

If I am not the right contact, I would appreciate being pointed to the right person.

Best regards,

Imsoo Ryoo
Co-Founder & AI Engineer
RISORIUS
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Yuki Tanabe,yuki-tan@editforce.jp,EditForce,RNA編集プログラムにおける脳波バイオマーカーの活用,"Yuki Tanabe 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

EditForce様はMTPC様とのCNS領域における提携を進められており、RNA編集技術のCNS応用に注力されていると拝察いたします。

CNS要素を持つ遺伝性疾患プログラムにおいて、客観的バイオマーカーは治療効果の定量化に寄与できるかと存じます。弊社のNeuro-Biomarker Co-Scientistは、EEGベースのAIでレスポンダーの早期特定を支援し、解析業務の効率化に寄与いたします。

オンプレミス運用に対応しておりますので、データ管理面でもご安心いただけるかと存じます。

2月16〜17日に東京へ伺います。ご都合のよいお時間をご教示いただけますでしょうか。Zoomでも対応可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
Takashi Ono,takashi-ono@editforce.jp,EditForce,CNS遺伝性疾患における治療効果の客観的測定,"Takashi Ono 様

突然のご連絡失礼いたします。リソリウスのリュ・イムスと申します。

※本メールがご不要でしたら、ご放念くださいませ。

EditForce様はMTPC様とのCNS領域における提携を進められ、RNA編集技術のCNS応用で着実にご実績を積まれていると拝察いたします。

CNS遺伝性疾患では、治療効果の客観的測定が課題になる場面もあるかと存じます。弊社のNeuro-Biomarker Co-Scientistは、EEGベースのAIでレスポンダーの早期特定を支援し、解析業務の効率化に寄与いたします。

オンプレミス運用に対応しておりますので、データ管理面でもご活用いただけるかと存じます。

2月16〜17日に東京へ伺います。お忙しいところ恐縮ですが、ご面談のお時間を頂戴できますでしょうか。Zoomも可能です。

何卒よろしくお願い申し上げます。

リュ・イムス
共同創業者 兼 AIエンジニア
リソリウス
Email: leiris@risorious.com
Tel: +82-10-9592-2268"
